Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)

Journal: Nature Communications

Published: 2021-05-03

DOI: 10.1038/s41467-021-22582-6

Affiliations: 26

Authors: 34

Go to article
Institutions Share
Clovis Oncology, United States of America (USA) 0.24
Foundation Medicine, Inc., United States of America (USA) 0.06
Mayo Clinic, United States of America (USA) 0.06
University of Washington (UW), United States of America (USA) 0.03
Banner - University Medical Center Tucson, United States of America (USA) 0.03
Austin Hospital, Austin Health, Australia 0.03
The University of Melbourne (UniMelb), Australia 0.03
Stanford Cancer Center, United States of America (USA) 0.03
Guy's and St Thomas' NHS Foundation Trust, United Kingdom (UK) 0.03
Alberta Health Services (AHS), Canada 0.03
Rocky Mountain Institute (RMI), United States of America (USA) 0.03
UCSF Medical Center, United States of America (USA) 0.03
Lawson Health Research Institute, Canada 0.03
Hospital of the University of Montreal (CHUM), Canada 0.03
Molecular Predictors and New Targets in Oncology, France 0.03
OSU Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James), United States of America (USA) 0.03
University of California, Los Angeles (UCLA), United States of America (USA) 0.03
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA) 0.03
The University of Texas MD Anderson Cancer Center, United States of America (USA) 0.03
Vall d'Hebron University Hospital (HUVH), ICS, Spain 0.03
Centre Léon Bérard (CLB), France 0.03
BC Cancer Agency (BCCA), PHSA, Canada 0.03
Princess Margaret Cancer Centre, U of T, Canada 0.03
Imperial College London (ICL), United Kingdom (UK) 0.03
Royal Melbourne Hospital (RMH), Australia 0.01
Walter and Eliza Hall Institute of Medical Research (WEHI), Australia 0.01

Return